These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 18566819)

  • 21. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
    Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
    J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.
    Fu L; Liu L; Zhang J; Xu B; Fan Y; Tian J
    Eur Radiol; 2014 Nov; 24(11):2800-9. PubMed ID: 25097125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analytic comparison between PIB-PET and FDG-PET results in Alzheimer's disease and MCI.
    He W; Liu D; Radua J; Li G; Han B; Sun Z
    Cell Biochem Biophys; 2015 Jan; 71(1):17-26. PubMed ID: 25370296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET.
    Tolboom N; Yaqub M; van der Flier WM; Boellaard R; Luurtsema G; Windhorst AD; Barkhof F; Scheltens P; Lammertsma AA; van Berckel BN
    J Nucl Med; 2009 Feb; 50(2):191-7. PubMed ID: 19164243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between biomarkers in aging and dementia.
    Jagust WJ; Landau SM; Shaw LM; Trojanowski JQ; Koeppe RA; Reiman EM; Foster NL; Petersen RC; Weiner MW; Price JC; Mathis CA;
    Neurology; 2009 Oct; 73(15):1193-9. PubMed ID: 19822868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
    Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging.
    Fripp J; Bourgeat P; Acosta O; Raniga P; Modat M; Pike KE; Jones G; O'Keefe G; Masters CL; Ames D; Ellis KA; Maruff P; Currie J; Villemagne VL; Rowe CC; Salvado O; Ourselin S
    Neuroimage; 2008 Nov; 43(3):430-9. PubMed ID: 18789389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
    Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
    Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Accuracy of Amyloid versus
    Lesman-Segev OH; La Joie R; Iaccarino L; Lobach I; Rosen HJ; Seo SW; Janabi M; Baker SL; Edwards L; Pham J; Olichney J; Boxer A; Huang E; Gorno-Tempini M; DeCarli C; Hepker M; Hwang JL; Miller BL; Spina S; Grinberg LT; Seeley WW; Jagust WJ; Rabinovici GD
    Ann Neurol; 2021 Feb; 89(2):389-401. PubMed ID: 33219525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.
    Okello A; Koivunen J; Edison P; Archer HA; Turkheimer FE; Någren K; Bullock R; Walker Z; Kennedy A; Fox NC; Rossor MN; Rinne JO; Brooks DJ
    Neurology; 2009 Sep; 73(10):754-60. PubMed ID: 19587325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.
    Cohen AD; Price JC; Weissfeld LA; James J; Rosario BL; Bi W; Nebes RD; Saxton JA; Snitz BE; Aizenstein HA; Wolk DA; Dekosky ST; Mathis CA; Klunk WE
    J Neurosci; 2009 Nov; 29(47):14770-8. PubMed ID: 19940172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.
    Wirth M; Oh H; Mormino EC; Markley C; Landau SM; Jagust WJ
    Alzheimers Dement; 2013 Nov; 9(6):687-698.e1. PubMed ID: 23474040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.